Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis — AI Research | MarketCI

REGN

Market Closed

Regeneron Pharmaceuticals, Inc.

NASDAQHealthcare Biotechnology

15.16K employees

CEO: Leonard S. Schleifer

Founded: 1991

$609.94

+$0.00(+NaN%)

Market Cap

62.84B

Beta

0.24

52W Range

N/A

Dividend Yield

0.62%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

REGN Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for REGN built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Buy

Pass %

71.43%

Score

5/7

Fair Value Estimate

Cash flow analysis • Multiple methods

$2,458.86

AI Price Target

Machine learning • Price prediction

$649.34

Market Sentiment

News & social media analysis

0.02

Value Investor Price

Classic value analysis

$218.03

Financial Health

Bankruptcy risk assessment

7.08

Quality Score

Financial strength rating

5.00

AI Investment Grade

Deep analysis of filings & news

58.00

Key Investment Highlights

Important factors affecting REGN investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

69.05% Good

Conditions Met

29.00/42.00

Due Diligence Score

69.05%

Due Diligence Conditions

Investment analysis conditions and results


	Pass
	Fail
	Fail
	Pass
	Fail
	Pass

Showing 1 to 6 of 46 conditions